Signaturefd LLC Cuts Position in argenx SE (NASDAQ:ARGX)

Signaturefd LLC lessened its holdings in argenx SE (NASDAQ:ARGX) by 3.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,365 shares of the company’s stock after selling 45 shares during the quarter. Signaturefd LLC’s holdings in argenx were worth $519,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Jennison Associates LLC lifted its stake in shares of argenx by 32.2% in the third quarter. Jennison Associates LLC now owns 1,511,745 shares of the company’s stock worth $743,219,000 after buying an additional 368,367 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its stake in shares of argenx by 339.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 581,586 shares of the company’s stock worth $285,925,000 after buying an additional 449,151 shares in the last quarter. RTW Investments LP lifted its stake in shares of argenx by 5.2% in the third quarter. RTW Investments LP now owns 507,195 shares of the company’s stock worth $249,352,000 after buying an additional 25,000 shares in the last quarter. Invesco Ltd. lifted its stake in shares of argenx by 377.0% in the third quarter. Invesco Ltd. now owns 430,787 shares of the company’s stock worth $211,788,000 after buying an additional 340,482 shares in the last quarter. Finally, Federated Hermes Inc. lifted its stake in shares of argenx by 7.4% in the fourth quarter. Federated Hermes Inc. now owns 356,507 shares of the company’s stock worth $135,626,000 after buying an additional 24,416 shares in the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ARGX. HC Wainwright restated a “buy” rating and set a $451.00 price objective on shares of argenx in a research report on Thursday, April 18th. Scotiabank increased their price objective on shares of argenx from $402.00 to $408.00 and gave the company a “sector perform” rating in a research report on Tuesday, March 26th. Wedbush restated an “outperform” rating and set a $521.00 price objective on shares of argenx in a research report on Thursday, April 18th. Robert W. Baird lowered their price objective on shares of argenx from $505.00 to $490.00 and set an “outperform” rating on the stock in a research report on Friday, March 1st. Finally, Wolfe Research began coverage on shares of argenx in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fourteen have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $528.16.

argenx Price Performance

Shares of NASDAQ ARGX opened at $375.00 on Thursday. The firm has a fifty day moving average price of $386.72 and a 200-day moving average price of $418.48. The stock has a market cap of $22.29 billion, a PE ratio of -72.96 and a beta of 0.65. argenx SE has a 1 year low of $327.73 and a 1 year high of $550.76.

argenx (NASDAQ:ARGX) last posted its earnings results on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing the consensus estimate of ($1.23) by ($0.45). The company had revenue of $417.84 million for the quarter, compared to analysts’ expectations of $378.60 million. argenx had a negative net margin of 23.26% and a negative return on equity of 16.97%. During the same period in the previous year, the business posted ($0.70) earnings per share. On average, research analysts expect that argenx SE will post -2.1 EPS for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.